Pfizer makes first investments through breakthrough growth fund pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology,.
Trillium
Therapeutics (NASDAQ:TRIL) climbed 1,330% last year, but unlike most of its soaring biotech stock peers, its business has nothing to do with fighting the SARS-CoV-2 coronavirus. It s an oncology specialist. And another banner year for investors could be coming in 2021 as the company gets more data from its cancer-fighting candidates and works toward a long-term goal of replacing a common method to treat the disease.
Image source: Getty Images
In a league of its own
Human cells have a certain protein on their surface that signals to the immune system not to attack them. Nearly all cancers boost this protein, called CD47, to protect themselves and avoid detection. In March,
Frazier Healthcare Partners Makes Promotions on Life Sciences Team
Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team.
These are Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.
Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.
Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.
Best Performing Stocks That Could Make Huge Gains In 2021.
You could say that 2020 was a very interesting year for the stock market. Retrospectively, we have had one heck of a rollercoaster ride this year. We saw the stock market crash in March no thanks to the coronavirus pandemic. Tech stocks have seen unprecedented gains this year while other stocks lost huge chunks of their value. 2020 was also the advent of the renewable energy/electric vehicle industries. We saw how biotech stocks that focused on vaccine development skyrocketed in valuation.Â
Moderna (MRNA Stock Report) for instance has seen its share price increase by over 450% year-to-date. The company has had its Phase 3 clinical trial data published in a peer-reviewed article yesterday. The article concludes that Modernaâs vaccine showed 94.1% efficacy, and no safety concerns were identified. The company truly has every right to be one of the best-performing stocks in 2020 given how it brought a working vaccine in